2 Biotech Stocks to Buy Hand Over Fist in 2023 and 1 to Avoid Like the Plague
Biotech stocks are like Wall Street's roulette wheel. While many pre-clinical and clinical-stage compounds will fail to make it to pharmacy shelves, those that do can have life-changing impacts on patients and patient investors.
Thanks to ongoing innovation, better diagnostic tools, and the incredible pricing power of brand-name therapeutics, Grand View Research expects a compound annual growth rate of nearly 14% from the global biotech industry through 2030. This would put worldwide biotech revenue on a path to reach almost $3.9 trillion by the turn of the decade. In other words, investing in this industry can be a genius move.
Image source: Getty Images.
Source Fool.com
